Log in to search using one of your social media accounts:

 

Here Come More Gene Therapies -- And More Pricing Debates

Gene therapies like Spark Therapeutics'upcoming Luxturna and Novartis'FDA-approved Kymriah are raising concerns about the rising cost of health care, leading some experts to suggest new ways to price treatments based on the benefits they offer.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Tags: NASDAQ:ONCE Source Type: news

Related Links:

Human Gene Therapy Nov 2017, Vol. 28, No. 11: 939-939.
Source: Human Gene Therapy - Category: Genetics & Stem Cells Authors: Source Type: research
Human Gene Therapy Nov 2017, Vol. 28, No. 11: 940-940.
Source: Human Gene Therapy - Category: Genetics & Stem Cells Authors: Source Type: research
Human Gene Therapy Nov 2017, Vol. 28, No. 11: 941-950.
Source: Human Gene Therapy - Category: Genetics & Stem Cells Authors: Source Type: research
Human Gene Therapy Nov 2017, Vol. 28, No. 11: 954-957.
Source: Human Gene Therapy - Category: Genetics & Stem Cells Authors: Source Type: research
Human Gene Therapy Nov 2017, Vol. 28, No. 11: 958-958.
Source: Human Gene Therapy - Category: Genetics & Stem Cells Authors: Source Type: research
Human Gene Therapy Nov 2017, Vol. 28, No. 11: 959-959.
Source: Human Gene Therapy - Category: Genetics & Stem Cells Authors: Source Type: research
Human Gene Therapy Nov 2017, Vol. 28, No. 11: 960-963.
Source: Human Gene Therapy - Category: Genetics & Stem Cells Authors: Source Type: research
Human Gene Therapy Nov 2017, Vol. 28, No. 11: 964-971.
Source: Human Gene Therapy - Category: Genetics & Stem Cells Authors: Source Type: research
Human Gene Therapy Nov 2017, Vol. 28, No. 11: 972-981.
Source: Human Gene Therapy - Category: Genetics & Stem Cells Authors: Source Type: research
Human Gene Therapy Nov 2017, Vol. 28, No. 11: 988-1003.
Source: Human Gene Therapy - Category: Genetics & Stem Cells Authors: Source Type: research
More News: Gene Therapy | Genetics | Health Management | Pharmaceuticals